Cortex Pharmaceuticals says it will resume a study of its lead drug for Alzheimer's after getting a green light from the FDA. The agency put trials of CX717 on hold last year after it voiced concerns regarding animal data. The drug is designed to strengthen the brain signals of patients and is also being studied for narcolepsy, ADHD and schizophrenia. Researchers say they will soon approach the FDA to gain approval for a Phase IIb trial of CX717 for ADHD.
- see the release
- check out the AP report on the trial
Related Articles:
FDA hold lifted on Cortex drug. Report
Cortex shares plunge on CX717 failure. Report
Cortex names Varney new COO. Report